<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820885</url>
  </required_header>
  <id_info>
    <org_study_id>CL0600-022</org_study_id>
    <nct_id>NCT00820885</nct_id>
  </id_info>
  <brief_title>A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide</brief_title>
  <official_title>A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to study the safety and tolerability of teduglutide
      following a once or possibly twice daily subcutaneous injection for eight consecutive days in
      healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide
      following a once or possibly twice daily injection for eight consecutive days in healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects are enrolled once they have been screened and it is determined they qualify.
      The subjects are randomized to either placebo or the dose of teduglutide as outlined by the
      protocol at a 1:3 ratio. They will be injected with investigational product for eight
      consecutive days, with measurements taken including safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Each dose arm is safe</measure>
    <time_frame>Within 1 week of each cohort completion</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Pharmacokinetics and Safety of Elevated Doses</condition>
  <arm_group>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 mg dose 20 mg/ML concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 mg in 50 mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>80mg in 50mg/ml concentration and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide</intervention_name>
    <description>subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.</description>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex is the brand name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide</intervention_name>
    <description>Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water</description>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tedguglutide</intervention_name>
    <description>lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.</description>
    <arm_group_label>cohort A</arm_group_label>
    <arm_group_label>Cohort AR</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort H</arm_group_label>
    <arm_group_label>cohort I</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between 20 and 55 years of age

          -  BMI of 18-35 inclusive

          -  Able to understand and sign informed consent form

          -  Willing and able to be confined at the clinical research center 8.5 days

          -  Women who are post-menopausal, surgically sterilized, or agree to use effective form
             of birth control

          -  Women of child bearing potential with a negative pregnancy test at screening and
             check-in

          -  Medically healthy with normal clinical results and ECG/lab profiles at screening and
             check-in

        Exclusion Criteria

          -  Donated 1 pint or more of blood/blood products within 56 days prior to study or
             received plasma within 7 days prior to study

          -  Pregnancy or become pregnant

          -  Participated in another investigational trial 30 days prior

          -  Physical examination/medical history indicates clinical condition or concurrent
             illness unsuitable for study

          -  History/presence of clincally significant disease of any body system

          -  History/evidence of congenital hon-hemolytic hyperbilirubinemia

          -  History/evidence of gall stone disease, stomach or intestinal surgery

          -  History/evidence of colorectal cancer

          -  History/evidence of GI disease, e.g., malabsorption, Crohn's Disease, etc.

          -  History/evidence of skin rashes or dermatitis

          -  Taking prescription or over the counter medication (with the exception of oral
             contraception) during the 7 days preceding confinement to the clinical unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Shaw, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator with Northwest Kinetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

